4.3.2.1: argininosuccinate lyase
This is an abbreviated version!
For detailed information about argininosuccinate lyase, go to the full flat file.
Word Map on EC 4.3.2.1
-
4.3.2.1
-
ornithine
-
arginase
-
citrulline
-
transcarbamylase
-
ammonia
-
aciduria
-
l-arginine
-
hyperammonemia
-
duck
-
delta-crystallins
-
carbamyl
-
lenses
-
carbamoyltransferase
-
carbamoylphosphate
-
citrullinemia
-
urea-cycle
-
n-acetylglutamate
-
ureotelic
-
medicine
-
ureogenesis
-
6.3.4.5
-
reptilian
-
pharmacology
-
drug development
-
diagnostics
-
analysis
- 4.3.2.1
- ornithine
- arginase
- citrulline
-
transcarbamylase
- ammonia
- aciduria
- l-arginine
-
hyperammonemia
- duck
-
delta-crystallins
-
carbamyl
- lenses
-
carbamoyltransferase
- carbamoylphosphate
- citrullinemia
-
urea-cycle
- n-acetylglutamate
-
ureotelic
- medicine
-
ureogenesis
-
6.3.4.5
-
reptilian
- pharmacology
- drug development
- diagnostics
- analysis
Reaction
Synonyms
AL, ARG4, ArgH, arginine-succinate lyase, argininosuccinase, Argininosuccinate lyase, argininosuccinic acid lyase, Arginosuccinase, ASAL, ASL, delta2 crystallin, delta2-crystallin, hASL, L-argininosuccinate arginine-lyase, lyase, argininosuccinate, Rv1659
ECTree
4.3.2.1 argininosuccinate lyaseAdvanced search results
results (
results (Application
Application on EC 4.3.2.1 - argininosuccinate lyase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
APPLICATION 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
analysis
-
the rapid and sensitive assay method is used to detect increases in the activity in serum from patients with liver diseases
diagnostics
drug development
argininosuccinate lyase (ASL) is overexpressed in breast cancer and downregulation of argininosuccinate lyase decreases tumor growth by inhibiting cyclin A2 and NO. Administration of ASL shRNA may be a treatment to prevent cancer cell proliferation and induce cancer cell death
medicine
pharmacology
argininosuccinate lyase (ASL) is overexpressed in breast cancer and downregulation of argininosuccinate lyase decreases tumor growth by inhibiting cyclin A2 and NO. Administration of ASL shRNA may be a treatment to prevent cancer cell proliferation and induce cancer cell death
diagnostics
-
the enzyme may be used as a candidate marker for serodiagnosis of brucellosis
diagnostics
-
the urea cycle metabolite argininosuccinate is a common metabolic biomarker of FH deficiency
diagnostics
-
the urea cycle metabolite argininosuccinate is a common metabolic biomarker of FH deficiency
diagnostics
-
the enzyme may be used as a candidate marker for serodiagnosis of brucellosis
-
medicine
-
argininosuccinate lyase is present in activated microglia cells in the ischemic rat
medicine
-
transient ischemia induces changes in the number and percentage of the nNOS+ neurons also expressing argininosuccinate lyase
medicine
-
argininosuccinate lyase is a valuable marker for estimating hepatopathy
medicine
-
expression of mutant ASL proteins in Escherichia coli. The known classical p.Q286R, the novel classical p.K315E and the known mutations p.I100T, p.E189G and p.R385C, which all have been linked to a mild phenotype of argininosuccinic aciduria, show no significant residual activity. There is some enzyme activity detected with the p.V178M (5% of wild-type), and p.R379C (10% of wild-type) mutations in which Km values for argininosuccinic acid differs significantly from the wild-type ASL protein
medicine
-
loss of function of fumarate hydratase, the mitochondrial tumor suppressor and tricarboxylic acid cycle enzyme, is associated with a highly malignant form of papillary and collecting duct renal cell cancer The accumulation of fumarate leads to reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells from Fh1-deficient humans, making these cells auxotrophic for arginine, which opens a therapeutic perspective for the cure of hereditary leiomyomatosis and renal cell cancer
medicine
-
manipulating the enzyme expression or activity might be of potential benefit for treatment of necrotizing enterocolitis
medicine
-
manipulating the enzyme expression or activity might be of potential benefit for treatment of necrotizing enterocolitis
medicine
-
the enzyme may serve as a target for manipulating NO production and treatment of NO-related diseases
medicine
argininosuccinate lyase (ASL) is overexpressed in breast cancer and downregulation of argininosuccinate lyase decreases tumor growth by inhibiting cyclin A2 and NO. Administration of ASL shRNA may be a treatment to prevent cancer cell proliferation and induce cancer cell death
